RC48-ADC in HER2-low Advanced Breast Cancer
ConditionAdvanced Breast Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorRenJi Hospital
About this trial
To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) as salvage treatment in patients with HER2-low advanced breast cancer who have received up to one previous chemotherapy for recurrent or metastatic disease without previous use of antibody-drug conjugate.
Eligibility criteria
Qualifiers
Female patients aged ≥18 years
Expected survival ≥12 weeks
ECOG 0-1
Histologically confirmed invasive advanced or metastatic breast cancer that is incurable and unresectable
Disqualifiers
History of thromboembolic events
Uncontrolled systemic diseases, including diabetes, hypertension, interstitial lung disease, cirrhosis, etc.
Active infections requiring systemic treatment
Pregnant or lactating
Trial design
Treatments tested in this trial
- Disitamab vedotin
Treatment groups
36 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov